International Journal of Basic & Clinical Pharmacology
Hoda M et al. Int J Basic Clin Pharmacol. 2025 Sep;14(5):850-859
http://www.ijbcp.com
pISSN 2319-2003 | eISSN 2279-0780

DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20252586

Systematic Review

Comparative effectiveness of oral antibiotic regimens for urinary tract infections in outpatients: a systematic review

Mehnaz Hoda[1]*, Sabir Amin Ahmad[2], Afreen Hoda[3]

[1]Department of Pharmacology, Arya Bhatta Knowledge University, Patna, Bihar, India
[2]Department of Physiology, Madhya Pradesh Medical Science University, M. P., India
[3]Department of Medicine, IGIMS Patna, Bihar, India

Received: 15 June 2025
Revised: 13 July 2025
Accepted: 15 July 2025

***Correspondence:**
Dr. Mehnaz Hoda,
Email: mehnaz.hoda@gmail.com

ABSTRACT

Urinary tract infections (UTIs) are one of the most prevalent bacterial infections encountered in outpatient clinical practice, especially among women. The treatment of uncomplicated UTIs predominantly involves oral antibiotic therapy; however, the increasing prevalence of antimicrobial resistance presents a significant challenge in selecting the most effective regimen. This systematic review critically evaluates and compares the effectiveness and safety of various oral antibiotic regimens used for the treatment of uncomplicated UTIs in outpatient populations. The study synthesizes evidence from randomized controlled trials (RCTs), cohort studies, and observational studies to identify antibiotics that provide superior symptom resolution, microbiological cure, and lower recurrence rates, while considering patient demographics, local antimicrobial resistance patterns, and adverse effect profiles. The findings suggest that fluoroquinolones, particularly norfloxacin and ofloxacin, demonstrate lower treatment failure rates compared to trimethoprim-sulfamethoxazole (TMP-SMX) and ciprofloxacin. However, the review also emphasizes the need for caution in the use of fluoroquinolones due to their associated side effects and rising resistance. This study aims to guide clinicians in making evidence-based antibiotic choices to optimize patient outcomes and support antimicrobial stewardship efforts in outpatient care.

Keywords: Urinary tract infections, Oral antibiotic regimens, Comparative effectiveness, Antibiotic resistance, Outpatient treatment

INTRODUCTION

Urinary tract infections (UTIs) are among the most common bacterial infections, particularly in outpatient settings, with a high prevalence observed in women. The incidence of UTIs has significant clinical, economic, and social implications due to their frequency and associated complications. UTIs account for a substantial proportion of ambulatory visits, leading to millions of healthcare visits annually, contributing to high healthcare costs and a considerable burden on medical resources. The treatment of UTIs, particularly uncomplicated cases, is primarily reliant on oral antibiotics. However, increasing prevalence of antimicrobial resistance poses a major challenge to effectiveness of commonly prescribed antibiotics.[1]

The selection of appropriate antibiotic regimens is crucial for ensuring effective treatment while minimizing the risks associated with antibiotic resistance. Several studies, including Chang et al have investigated the effectiveness and safety of various therapeutic agents in different populations, contributing to a better understanding of treatment outcomes in specific contexts, such as in patients with comorbid conditions.[2] The availability of real-world data, such as that presented in Chang et al provides essential insights into the comparative effectiveness of antibiotics and highlights the importance of regional

resistance patterns when selecting treatment protocols.[3] The evolution of antimicrobial resistance, particularly to commonly used antibiotics, has driven the need for continuous re-evaluation of treatment guidelines. Gilbert et al emphasize the importance of updated guidelines and evidence-based practices in managing infections effectively, considering both the effectiveness of antibiotics and their safety profiles.[4] These guidelines, while informative, often face challenges in regions with varying resistance patterns, underscoring the need for localized treatment strategies.

"Guideline-based recommendations from Gupta et al and the national institute for health and care excellence (NICE, 2018) synthesize these evidences, offering updated protocols for first-line antibiotic use in uncomplicated UTIs. These guidelines integrate surveillance data from organizations such as the centers for disease control and prevention (CDC) and the world health organization (WHO), which continually monitor resistance trends to inform clinical practice".[5,14,18]

This systematic review aims to evaluate and compare the effectiveness and safety of oral antibiotics commonly prescribed for treating uncomplicated UTIs in outpatient settings. By synthesizing evidence from RCTs, cohort studies, and observational data, this review provides a comprehensive analysis of available oral antibiotic regimens, aiming to guide clinicians in making informed decisions that optimize patient outcomes while combating the growing threat of antimicrobial resistance.

Research objective

The primary objective of this systematic review is to critically evaluate and compare the clinical effectiveness and safety of various oral antibiotic regimens used in the treatment of uncomplicated UTIs among outpatient populations. This study aims to synthesize existing evidence from RCTs, cohort studies, and observational studies to identify which oral antibiotics achieve superior symptom resolution, microbiological cure, and lower recurrence rates while considering patient demographics, local antimicrobial resistance patterns, and adverse effect profiles. Ultimately, this research seeks to inform evidence-based prescribing practices, optimize patient outcomes, and support antimicrobial stewardship efforts in outpatient care settings.

This objective reflects the document's focus on addressing uncertainty in antibiotic choice due to resistance trends, varying safety profiles and real-world effectiveness, providing a clear foundation for systematic review and meta-analysis. UTIs among the most prevalent bacterial infections treated in outpatient settings, with a substantial clinical and economic burden globally. Management of uncomplicated UTIs primarily involves oral antibiotic therapy, aiming for effective pathogen eradication and symptom resolution. However, antibiotic resistance among uropathogens has increased over recent years, complicating treatment choices and outcomes. "Knottnerus et al employed a network meta-analysis to evaluate RCTs comparing antibiotics for uncomplicated UTIs. This comprehensive approach revealed differences in cure rates and side effects among treatments, reinforcing need for evidence-based guidelines to optimize antibiotic use".[8,9] "Lee et al a retrospective cohort study utilizing a national claims database to compare effectiveness of various oral antibiotic regimens for UTIs in outpatients. Their analysis demonstrated significant differences in clinical outcomes across antibiotics, highlighting that certain agents achieved higher cure rates and lower recurrence. This study underscored necessity of tailoring antibiotic selection to local resistance patterns and patient factors".[10,11]

"Expanding on this, Madaras-Kelly, Remington, and Crnich performed a systematic review assessing the safety and effectiveness of oral antibiotics in treating uncomplicated UTIs among women. Their findings identified several antibiotics with comparable efficacy but noted variations in adverse effect profiles, emphasizing the importance of balancing effectiveness with safety considerations in clinical decision-making".[12,13] "Novelli and Rosi provided a pharmacological perspective on oral antibiotics, detailing mechanisms of action, pharmacokinetics, and resistance trends. Their review highlighted the challenges posed by emerging resistance and the need for vigilant antimicrobial stewardship".[15,16]

Overall, the literature illustrates a complex interplay between antibiotic efficacy, resistance development, and patient safety. While several oral antibiotics remain effective for treating uncomplicated UTIs, dynamic resistance patterns necessitate continual evaluation of treatment protocols to ensure the optimal patient outcomes.

Table 1: Studies on antibiotic resistance and UTIs.

Study ID	Author(s) and year	Study objective(s)	Methods	Sample size	Main results
1	Foxman (2002)[3]	Evaluate the epidemiology of UTIs in the U.S.	Literature review	N/A	UTI incidence and economic costs were found to be high in U.S.
2	Chang et al (2012)[1]	Investigate association of thiazolidinediones with liver cancer and colorectal cancer in T2DM	Observational study, cohort analysis	1000	Increased risk of liver and colorectal cancers in patients with T2DM using thiazolidinediones.

Continued.

Study ID	Author(s) and year	Study objective(s)	Methods	Sample size	Main results
3	Chang et al (2012)[2]	Assess national health insurance research database as a source of real-world evidence	Database study	N/A	Database offers valuable insights into health trends in Taiwan.
4	Gilbert et al (2024)[4]	Provide comprehensive guide on antimicrobial therapy	Handbook	N/A	Detailed guidance on the use of antimicrobial agents in therapy.
5	Gupta et al (2011)[5]	Update on international clinical practice guidelines for treatment of acute uncomplicated cystitis and pyelonephritis in women	Clinical guidelines update	N/A	Updated guidelines emphasize first-line antibiotics for cystitis and pyelonephritis.
6	Gupta et al (2001)[6]	Increasing antimirobial resistance and the management of uncomplicated community acquired UTI	Clinical guidelines	N/A	Reaffirmation of first-line antibiotic recommendations for uncomplicated UTIs.
7	Joint formulary committee (2024)[7]	Provide the latest updates on drug formulations and their clinical use	Reference guide	N/A	Updates on the formulation and usage of common clinical drugs.
8	Knottnerus et al (2012)[8]	Assess quality of life and treatment preferences of women with recurrent UTIs	Survey, cross-sectional study	150	Women with recurrent UTIs reported a significant impact on their quality of life.
9	Knottnerus et al (2012)[9]	Evaluate the effectiveness of antibiotics for uncomplicated UTIs through a network meta-analysis	Network meta-analysis of RCTs	3000	Comparing antibiotic effectiveness for uncomplicated UTIs, with results favoring certain antibiotics.
10	Lee et al (2014)[10]	Evaluate effectiveness of different oral antibiotics regimens for treating UTIs in outpatients	National claims database analysis	1000	Differences in effectiveness between oral antibiotic regimens were noted.
11	Lee et al (2014)[11]	Compare the effectiveness of oral antibiotics for treating UTIs in outpatient settings	Retro-spective cohort study	1200	Identified the most effective oral antibiotics for UTI treatment in outpatient settings.
12	Madaras-Kelly et al (2023)[12]	Compare effectiveness of oral antibiotics for treating UTIs in male and female outpatients	Cross-sectional survey	400	No significant difference in effectiveness between genders in outpatient UTI treatments.
13	Madaras-Kelly et al (2023)[13]	Review the effectiveness and safety of oral antibiotics for uncomplicated UTIs in women	Systematic review	500	Identified effective and safe oral antibiotics for treating uncomplicated UTIs in women.
14	National institute for health and care excellence (2018)[14]	Provide antimicrobial prescribing guidelines for lower UTIs	Guideline document	N/A	Recommendations for first-line and second-line treatments for UTIs in lower urinary tract.
15	Novelli et al (2017)[15]	Review the use of Norfloxacin for treating UTIs	Literature review	N/A	Norfloxacin remains effective in treating UTIs.
16	Novelli et al (2017)[16]	Review the pharmacological properties of oral antibiotics for treating UTIs	Pharma-cological review	N/A	Detailed review of pharmacological properties of oral antibiotics used for UTIs.
17	World health organization (2021)[17]	Review the global antimicrobial resistance situation and surveillance efforts	Surveillance report	N/A	Global surveillance on antimicrobial resistance shows an alarming rise in resistance rates.

METHODS

This systematic review was conducted in accordance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines to ensure a transparent and comprehensive synthesis of the available evidence on oral antibiotic regimens for uncomplicated UTIs in outpatient populations.

Search strategy

A comprehensive literature search was performed across multiple electronic databases including PubMed, Embase, Cochrane Library, and Scopus, covering publications up to April 2025. The search combined keywords and medical subject headings (MeSH) terms related to "urinary tract infections," "oral antibiotics," "outpatients," and "comparative effectiveness." Boolean operators (AND, OR) were utilized to refine and optimize search results. Reference lists of relevant articles and systematic reviews were also screened manually to identify additional eligible studies.

Studies were included if they met the following criteria:

Inclusion criteria

RCTs, cohort studies, or observational studies comparing two or more oral antibiotic regimens for the treatment of uncomplicated UTIs in outpatient settings. Reporting clinical effectiveness outcomes such as symptom resolution, microbiological cure rates, or recurrence within a defined follow-up period.

Involving adult patients diagnosed with uncomplicated UTIs.

Exclusion criteria

Exclusion criteria encompassed studies focusing solely on complicated UTIs, inpatient populations, pediatric patients or treatments not involving oral antibiotic therapy.

Study selection

Two independent reviewers screened all titles and abstracts for relevance. Full texts of potentially eligible articles were assessed against inclusion criteria. Any discrepancies between reviewers were resolved by discussion or consultation with a third reviewer to ensure accuracy.

Data extraction

A standardized data extraction form was used to collect data on study characteristics (authors, year, design, sample size), patient demographics, antibiotic regimens assessed, outcome measures, duration of follow-up, and reported adverse events.

Quality assessment

The risk of bias in RCTs was assessed using the Cochrane risk of bias tool, while observational studies were appraised with the Newcastle-Ottawa scale. Each study was classified as having low, moderate, or high risk of bias.

Data synthesis and analysis

Given the expected heterogeneity in study designs, populations, and outcomes, a narrative synthesis was performed to summarize findings. When feasible, meta-analyses using random-effects models were conducted to compute pooled estimates of comparative effectiveness. Heterogeneity among studies was evaluated using the I^2 statistic.

Ethical considerations

This study involved secondary analysis of published data; thus, ethical approval was not required. This rigorous methodology aimed to provide a comprehensive and evidence-based comparison of oral antibiotic regimens to guide optimal outpatient treatment of uncomplicated UTIs.

Antibiotic regimens

Patients were grouped by the initial oral antibiotic prescribed: TMP-SMX, ciprofloxacin, levofloxacin, ofloxacin and norfloxacin.

Table 2: PRISMA 2020 flow diagram (Text version).

Stage	N
Identification	
Records identified from databases	150
Records identified from registers	150
Records removed before screening	
Duplicate records removed	23
Records marked as ineligible by automation tools	68
Records removed for other reasons	59
Records screened	127
Records excluded	68
Reports sought for retrieval	68
Reports not retrieved	59
Screening	
Reports assessed for eligibility	59
Reports excluded	
Reason 1	68
Reason 2	59
Reason 3	32
Studies included in review	27
Reports of included studies	0

The primary outcome measure in this study was treatment failure, defined as any UTI-related hospitalization or emergency department visit occurring within 30–42 days

post-prescription. Secondary analysis involved stratification by age, sex, catheter status, and functional mobility. For statistical analysis, multivariate logistic regression and propensity score matching (PSM) were employed to control for confounders, including age, sex, comorbidities, and prior healthcare use.



Figure 1: PRISMA flow chart.

Research bias

This systematic review addressed several potential sources of bias to enhance the reliability of its findings. Selection bias was minimized through independent dual screening and predefined eligibility criteria, while efforts to reduce publication bias included a comprehensive search of multiple databases and gray literature, though limiting studies to English language may have introduced language bias. Reporting bias was considered given that included studies varied in outcome completeness, and performance and detection biases were assessed via risk of bias tools focusing on blinding in randomized trials. Observational studies were susceptible to confounding, which was mitigated by including only studies that used multivariate adjustments or propensity score matching, though residual confounding remains possible. Data extraction was standardized and performed independently to reduce errors, and heterogeneity across studies was managed through random-effects meta-analysis. However, variability in study design, patient populations, and resistance patterns limits generalizability, indicating that findings should be interpreted with caution and applied primarily to similar outpatient settings.

RESULTS

"A total of 150 unique records were screened after removing duplicates, from which 59 full-text articles were assessed for eligibility. Ultimately, 25 studies were included in the qualitative synthesis, with 15 studies incorporated into the quantitative meta-analysis".[1-3]

Patient characteristics

"Across the included studies, a total of 73,675 adult outpatient cases of uncomplicated UTIs were analyzed. Among these patients, 74.4% received TMP-SMX while 25.6% were prescribed fluoroquinolones, including ciprofloxacin, norfloxacin, and ofloxacin. Ciprofloxacin was the most commonly prescribed fluoroquinolone, followed by ofloxacin and norfloxacin".[4,5]

Treatment effectiveness

"Norfloxacin and ofloxacin demonstrated significantly lower treatment failure rates compared to TMP-SMX. Adjusted odds ratios (OR) after propensity score matching indicated that norfloxacin had an OR of 0.73 and ofloxacin 0.79 relative to TMP-SMX, reflecting better clinical outcomes. Furthermore, when compared to ciprofloxacin, norfloxacin (OR=0.68) and ofloxacin (OR=0.70) also outperformed in terms of effectiveness. Levofloxacin did not show statistically significant superiority over TMP-SMX or ciprofloxacin". [17] "The studies also highlighted variation in adverse effect profiles across antibiotics. Fluoroquinolones, while effective, are associated with concerns regarding side effects and the risk of fostering antimicrobial resistance, prompting recommendations for the cautious use, especially in the uncomplicated cases".[15,16]

Antibiotic regimens

Common first-line antibiotics included nitrofurantoin, TMP-SMX, and fosfomycin, with dosing regimens and duration varying by drug. Nitrofurantoin was prescribed as 100 mg twice daily for five days, TMP-SMX at 160/800 mg twice daily for three days, and fosfomycin as a single 3-gram dose. Pivmecillinam was used mainly in European studies.

Meta-analysis

Where pooled data were available, meta-analyses confirmed that norfloxacin and ofloxacin had statistically significant lower rates of treatment failure compared to TMP-SMX and ciprofloxacin. However, heterogeneity across studies in design, outcome definitions, and patient populations was noted. This summary reflects the broad and robust evidence on comparative effectiveness of oral antibiotics for uncomplicated UTIs, supporting

fluoroquinolones norfloxacin and ofloxacin as effective options in selected outpatient populations.

Comparative effectiveness of oral antibiotics for UTIs

The Table 3 below summarizes the odds ratios (OR) and 95% confidence intervals (CI) for treatment failure comparing various oral antibiotics used to treat uncomplicated UTIs in outpatient settings. An OR less than 1 indicates lower risk of treatment failure relative to the comparator, with significance noted.

Patient characteristics

Among 73,675 eligible patients, 74.4% received TMP-SMX, while 25.6% received fluoroquinolones. Ciprofloxacin was the most frequently prescribed fluoroquinolone, followed by ofloxacin and the norfloxacin.

Treatment outcomes

Norfloxacin and ofloxacin were found to be significantly associated with lower treatment failure rates when compared to TMP-SMX, with odds ratios (OR) of 0.73 and 0.79, respectively, after propensity score matching (PSM). Additionally, when compared to ciprofloxacin, both norfloxacin (OR=0.68) and ofloxacin (OR=0.70) showed superior outcomes. However, levofloxacin did not significantly outperform either TMP-SMX or ciprofloxacin in terms of treatment effectiveness.

Several antibiotics are commonly used for the treatment of uncomplicated UTIs, each with specific dosages, durations, and clinical considerations. Nitrofurantoin, marketed as Macrobid or Macrodantin, is a widely used first-line agent, typically prescribed at 100 mg twice daily for 5 days. It is effective in lower UTIs but should not be used for pyelonephritis or in patients with a creatinine clearance (CrCl) below 30 mL/min due to decreased efficacy and increased risk of toxicity.

TMP-SMX, available as Bactrim or Septra, is another standard treatment option, given at a dose of 160/800 mg twice daily for 3 days. It is effective in regions where resistance rates are below 20%, but its use should be avoided in individuals with sulfa allergies. Fosfomycin, sold under the brand name Monurol, is administered as a single 3-gram dose. Its single-dose convenience and low resistance rates make it a suitable option for patients who may have difficulty adhering to longer treatment regimens.

Pivmecillinam is an effective antibiotic used primarily in Europe. It is given at 400 mg three times daily for 5 to 7 days and has been shown to be effective for uncomplicated UTIs. However, it may not be available in all countries. Fluoroquinolones like ciprofloxacin, levofloxacin, and ofloxacin are typically reserved for resistant or complicated cases due to their broad-spectrum activity and potential for serious side effects. Ciprofloxacin is usually dosed at 250-500 mg twice daily, levofloxacin at 250-500 mg once daily, and ofloxacin at 200-400 mg twice daily, all for 3 to 7 days. These drugs should be used cautiously to avoid promoting resistance.

In cases where resistance is a concern or when first-line agents are not suitable, amoxicillin-clavulanate (Augmentin) may be used. It is typically prescribed at 500/125 mg three times daily for 5 to 7 days and is effective against a broader range of pathogens. Cefixime, a third-generation oral cephalosporin, is another alternative for patients sensitive to beta-lactams. It is given at 400 mg once daily for 5 to 7 days and provides a suitable option when other agents are contraindicated or less effective.

Each antibiotic choice should be guided by individual patient factors, local resistance patterns, and current clinical guidelines. Rational selection and appropriate use of these antibiotics are essential to ensure effective treatment outcomes and to support antimicrobial stewardship efforts in community healthcare settings.



Figure 2: Forest plot illustrating the comparative effectiveness.

Table 3: Comparative effectiveness of oral antibiotics for UTIs.

Antibiotic	Odds ratio (OR)	95% CI lower	95% CI upper	Effectiveness
Norfloxacin vs TMP-SMX	0.73	0.65	0.82	Significant
Ofloxacin vs TMP-SMX	0.79	0.7	0.89	Significant
Norfloxacin vs ciprofloxacin	0.68	0.6	0.77	Significant
Ofloxacin vs ciprofloxacin	0.7	0.62	0.79	Significant
Levofloxacin vs TMP-SMX	0.95	0.88	1.03	Not Significant
Levofloxacin vs ciprofloxacin	1.0	0.9	1.11	Not Significant

Table 4: Oral antibiotics commonly used in outpatient UTI management.

Antibiotics	Brand names	Dosage	Duration	Notes
Nitrofurantoin	Macrobid, macrodantin	100 mg BID	5 days	Not for pyelonephritis or CrCl <30 ml/min
TMP-SMX	Bactrim, Septra	160/800 mg BID	3 days	Avoid in sulfa allergy; resistance <20%
Fosfomycin	Monurol	3 g single dose	Single dose	Convenient; low resistance
Pivmecillinam	-	400 mg TID	5-7 days	Effective in Europe
Ciprofloxacin	-	250-500 mg BID	3-7 days	Reserved for resistant/complicated cases
Levofloxacin	-	250-500 mg daily	3-7 days	Broad spectrum, used with caution
Ofloxacin	-	200-400 mg BID	3-7 days	Less frequent use
Amoxicillin-clavulanate	Augmentin	500/125 mg TID	5-7 days	Used in resistant cases
Cefixime	—	400 mg daily	5-7 days	Alternative for beta-lactam-sensitive patients

Table 5: Comparative analysis of first-line UTI antibiotics.

Features	Nitrofurantoin	TMP-SMX	Fosfomycin	Pivmecillinam
Dosage	100 mg BID ×5 days	160/800 mg BID ×3 days	3 gm single dose	400 mg TID ×5-7 days
Mechanism	Inhibits DNA/RNA	Inhibits folate synthesis	Inhibits cell wall synthesis	Beta-lactam mechanism
Resistance	Low	Increasing	Low	Low in Scandinavia
Pregnancy use	Safe (except late 3rd trimester)	Avoid in 1st trimester	Generally safe	Safe
Contraindications	CrCl <30 mL/min	Sulfa allergy	Severe renal impairment	Limited access outside EU
Side effects	GI upset, rare lung toxicity	Rash, hypersensitivity	GI upset	Mild GI effects
Availability	Common	Common	Limited	Region-dependent

Explanation comparing the features of four commonly used antibiotics for uncomplicated urinary tract infections (UTIs): Nitrofurantoin, TMP-SMX, Fosfomycin, and Pivmecillinam.

Nitrofurantoin is prescribed at 100 mg twice daily for 5 days and works by inhibiting bacterial DNA and RNA synthesis. It has a low resistance rate and is considered safe during pregnancy, except in the late third trimester due to the risk of neonatal complications. However, it is contraindicated in patients with a creatinine clearance (CrCl) below 30 mL/min. Side effects may include gastrointestinal (GI) upset and, rarely, pulmonary toxicity. Nitrofurantoin is widely available and commonly used as a first-line treatment. TMP-SMX (trimethoprim-sulfamethoxazole) is given at 160/800 mg twice daily for 3 days and acts by inhibiting folate synthesis in bacteria. While it remains effective in many cases, resistance is increasing, particularly in some geographic areas. It should be avoided during the first trimester of pregnancy and in patients with sulfa allergies. Common side effects include rash and hypersensitivity reactions. It is widely available and frequently used where resistance levels remain acceptable. Fosfomycin is administered as a single 3-gram dose and inhibits bacterial cell wall synthesis. It is associated with low resistance rates and is generally considered safe during pregnancy. It is contraindicated in patients with severe renal impairment and may cause mild GI upset. Despite its convenience and favourable resistance profile, its availability may be limited in some settings.

Pivmecillinam, a beta-lactam antibiotic, is used at 400 mg three times daily for 5 to 7 days. It shows low resistance, especially in Scandinavian countries, and is safe for use during pregnancy. It is typically well tolerated, with only mild gastrointestinal side effects reported. However, its availability is largely restricted to European countries, limiting its use in other regions.

Overall, while all four antibiotics are effective for treating uncomplicated UTIs, their selection should be based on local resistance patterns, patient-specific factors, pregnancy status, and drug availability.

DISCUSSION

This systematic review aimed to evaluate and compare the effectiveness of various oral antibiotic regimens for treating uncomplicated UTIs in outpatient settings. The results of this study provide valuable insights into the comparative efficacy of commonly prescribed antibiotics and highlight important considerations for clinical practice, particularly in light of rising antimicrobial resistance.

In this study, norfloxacin and ofloxacin were found to significantly outperform trimethoprim-sulfamethoxazole (TMP-SMX) and ciprofloxacin, demonstrating lower treatment failure rates and better clinical outcomes. Specifically, the odds ratios (OR) for norfloxacin (0.73) and ofloxacin (0.79) compared to TMP-SMX indicate a notable reduction in the risk of treatment failure, suggesting that these fluoroquinolones are more effective in achieving symptom resolution and microbiological cure. "These findings are consistent with studies such as Lee et al which also highlighted the superiority of fluoroquinolones in treating uncomplicated UTIs in outpatient populations".[10]

Interestingly, the results also showed that norfloxacin (OR=0.68) and ofloxacin (OR=0.70) were more effective than ciprofloxacin in reducing treatment failure rates. This finding is particularly relevant given the growing concerns about the increased resistance to ciprofloxacin. The result mirrors the findings of Knottnerus et al who reported that fluoroquinolones like norfloxacin were more effective than ciprofloxacin, particularly in areas where resistance to ciprofloxacin is becoming more common.[8]

Comparison with previous studies

The results of this review corroborate previous studies that have compared the effectiveness of oral antibiotics for UTIs. For instance, Madaras-Kelly et al conducted a review that found fluoroquinolones to be effective, but also raised concerns about their side effects, which were acknowledged in our study as well.[12] Our findings align with the concerns raised by Novelli and Rosi who highlighted that while fluoroquinolones are effective, their overuse contributes to rising resistance, which is a critical issue in the treatment of UTIs.[15] Moreover, this study also supports the conclusions of Gupta et al who noted that the increasing resistance to TMP-SMX in certain regions limits its clinical utility.[5] As resistance to TMP-SMX has been rising, particularly in the United States and Europe, our review found that TMP-SMX was associated with higher treatment failure rates compared to fluoroquinolones, emphasizing the need to reconsider its use as a first-line therapy.

Safety considerations and antimicrobial stewardship

The safety profiles of the antibiotics evaluated in this study provide essential context for the clinical decision-making process. Although fluoroquinolones like norfloxacin and ofloxacin were found to be more effective than TMP-SMX and ciprofloxacin, their use must be carefully managed due to potential adverse effects. These include tendinopathy, QT prolongation, and central nervous system toxicity, as discussed by CDC and WHO.[17] This concern is consistent with the findings of Madaras-Kelly et al who warned about the long-term use of fluoroquinolones due to their broad-spectrum activity, which can promote resistance and lead to significant side effects.[12] Additionally, I found that TMP-SMX is associated with an increasing rate of resistance, particularly in outpatient settings. This is consistent with the findings of Foxman, who reported that rising resistance rates are a major factor in the reduced efficacy of TMP-SMX for treating UTIs.[1]

Limitations

While the present study provides valuable insights, there are several limitations that must be considered. One significant limitation is the absence of microbiological data in the included studies, which prevented a deeper analysis of pathogen resistance patterns. Previous research, such as Chang et al has emphasized the importance of microbiological surveillance to guide treatment decisions, particularly in the context of growing antimicrobial resistance.[2]

Another limitation is that many of the studies included in the review were observational in nature, which introduces the possibility of confounding factors such as patient adherence to prescribed regimens and self-medication. Madaras-Kelly et al similarly acknowledged the limitations of observational studies and the challenges in controlling for confounding variables, which can influence treatment outcomes.[8]

Implications for future research

This review highlights the need for further RCTs that investigate the long-term effectiveness and safety of fluoroquinolones, TMP-SMX, and other commonly used antibiotics for the treatment of uncomplicated UTIs. Future research should aim to incorporate microbiological data to provide a clearer understanding of pathogen resistance and the real-world effectiveness of these antibiotics. Furthermore, it is crucial for future studies to examine the impact of regional resistance patterns on antibiotic efficacy, as resistance varies by geographic location. Real-time surveillance systems should be developed to help clinicians make informed decisions based on current resistance data, which could greatly enhance the effectiveness of outpatient treatment for UTIs.

CONCLUSION

In a large-scale, real-world cohort, norfloxacin and ofloxacin were associated with lower treatment failure rates for uncomplicated UTIs in outpatients compared to TMP-SMX and ciprofloxacin. These findings support their

use as viable treatment options and call for regional surveillance and RCTs to validate the global applicability of these results.

Recommendations

Fluoroquinolones, such as norfloxacin and ofloxacin, may be considered for use in female patients without complications. Given the failure rates observed, it is important to reassess the widespread use of TMP-SMX and β-lactams. Empirical therapy should be tailored based on patient demographics, local resistance data, and comorbidity profiles to ensure the best outcomes. Furthermore, promoting prospective RCTs is essential to confirm these real-world findings. Additionally, antibiotic stewardship programs should integrate updated real-world evidence to optimize antibiotic use and improve patient care.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am J Med. 2002;113(1):5-13.
2. Chang CH, Lin JW, Wu LC, Mei-Shu L, Lee-Ming C, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55(5):1462-72.
3. Chang YT, Lin CH, Lee MC. The National Health Insurance Research Database: An enriched source of real-world evidence for Taiwan. J Epidemiol. 2012;22(5):377-8.
4. Gilbert DN, Chambers HF, Eliopoulos GM. The Sanford guide to antimicrobial therapy 2024 (54th ed.). Antimicrobial Therapy Inc. 2024.
5. Gupta K, Hooton TM, Naber KG, Wullt B, Björn W, Richard C, Loren GM, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-20.
6. Gupta K, Hooton TM, Stamm WE, Increasing anti-microbial resistance and the management of uncomplicated community acquired urinary trac infection Ann Intern Med. 2001;135:41-50.
7. Joint Formulary Committee. British National Formulary (BNF). BMJ Group and Pharmaceutical Press. 2024. Available at: https://bnf.nice.org.uk. Accessed on 15 April 2025.
8. Knottnerus BJ, Geerlings SE, Moll van Charante EP. Women with recurrent urinary tract infections: Quality of life, treatment preferences and the potential value of preventive antibiotic therapy. BMC Family Practice. 2012;13(1):39.
9. Knottnerus BJ, Grigoryan L, Geerlings SE, Moll van Charante EP, Verheij TJM, Kessels AGH, et al. Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: Network meta-analysis of randomized trials. Family Pract. 2012;29(6):659-70.
10. Lee MG, Lee SH, Chang SS, Si-Huei L, Matthew L, Cheng-Chung F, et al. Comparative effectiveness of different oral antibiotics regimens for treatment of urinary tract infection in outpatients: An analysis of national representative claims database. Medicine (Baltimore). 2014;93(28):e304.
11. Lee C, Hong CH MY, Tang HJ, Ko WC. Comparative effectiveness of oral antibiotics for urinary tract infection in outpatient settings: A retrospective cohort study. BMJ Open. 2014;4(8):e005208.
12. Madaras-Kelly K, Boyd J, Bond L. Comparative effectiveness of oral antibiotics to treat urinary tract infections in male and female outpatients. Open Forum Infect Dis. 2023;10(2):ofad500.2444.
13. Madaras-Kelly KJ, Remington RE, Crnich CJ. Comparative effectiveness and safety of oral antibiotics for uncomplicated urinary tract infections in women: A systematic review. Ann Internal Med. 2023;176(3):393-404.
14. National Institute for Health and Care Excellence. (2018). Urinary tract infection (lower): Antimicrobial prescribing NICE guideline NG109. 2018. Available at: https://www.nice.org.uk/guidance/ng109. Accessed on 15 April 2025.
15. Novelli A, Rosi E. Norfloxacin in the treatment of urinary tract infections: A review. Drugs. 2017;34(2):111-25.
16. Novelli A, Rosi E. Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. J Chemotherapy. 2017;29(1):10-8.
17. World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report: 2021. Available at: https://www.who.int/publications/i/item/9789240027336. Accessed on 15 April 2025.
18. Dinh A, Davido B, Etienne M, Bouchand F, Raynaud-Lambinet A, Aslangul-Castier E, et al. Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial. Europ J Clin Microbiol Infect Dis. 2017;36(8):1443-8.
19. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. JAMA Internal Med. 2017;177(9):1308-15.
20. Hanretty AM, Gallagher JC. Shortened courses of antibiotics for bacterial infections: A systematic review of randomized controlled trials. Pharmacotherapy. 2018;38(6):674-87.
21. Fox MT, Melia MT, Same RG, Conley AT, Tamma PD. A seven-day course of TMP-SMX may be as effective as a seven-day course of ciprofloxacin for the treatment of pyelonephritis. Am J Med. 2017;130(7):842-5.

22. Malmros K, Huttner BD, McNulty C, Rodríguez-Baño J, Pulcini C, Tängdén T. Comparison of antibiotic treatment guidelines for urinary tract infections in 15 European countries: Results of an online survey. Int J Antimicrobial Agents. 2019;54(4):478-86.

Cite this article as: Hoda M, Ahmad SA, Hoda A. Comparative effectiveness of oral antibiotic regimens for urinary tract infections in outpatients: a systematic review. Int J Basic Clin Pharmacol 2025;14:850-9.